Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Chlamydia trachomatis | glutamine binding protein | 0.0058 | 0.0349 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0127 | 0.9706 | 0.9604 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0129 | 1 | 1 |
Schistosoma mansoni | 6-phosphofructokinase | 0.0129 | 1 | 0.5 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein | 0.0058 | 0.0349 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0127 | 0.9706 | 0.9706 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.0129 | 1 | 1 |
Mycobacterium tuberculosis | Probable glutamine-binding lipoprotein GlnH (GLNBP) | 0.0058 | 0.0349 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0129 | 1 | 1 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.0076 | 0.2852 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0127 | 0.9706 | 0.9706 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0129 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0076 | 0.2852 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0076 | 0.2852 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0129 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0076 | 0.2852 | 0.5 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.0076 | 0.2852 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0129 | 1 | 1 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein (hisJ) | 0.0058 | 0.0349 | 0.5 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0127 | 0.9706 | 0.9706 |
Onchocerca volvulus | 0.0129 | 1 | 0.5 | |
Chlamydia trachomatis | arginine ABC transporter substrate-binding protein ArtJ | 0.0058 | 0.0349 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.0127 | 0.9706 | 0.9706 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Reduction (functional) | 0 % | Percent reduction of edema in rat on 23rd day after oral administration of 30 mg/kg in antiarthritis assay; i = Inactive | ChEMBL. | 6606043 |
Reduction (functional) | = 18.9 % | Percent reduction of edema in mice 3h after oral administration of 30 mg/kg in carrageenin model | ChEMBL. | 6606043 |
Reduction (functional) | = 18.9 % | Percent reduction of edema in mice 3h after oral administration of 30 mg/kg in carrageenin model | ChEMBL. | 6606043 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.